Download PDF
Zeitschrift für Phytotherapie 2013; 34(03): 116-120
DOI: 10.1055/s-0032-1331497
Übersicht
Johanniskraut
© Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Johanniskraut in der Onkologie – Perspektiven auf eines der bekanntesten Phytotherapeutika

Nikolaus Stosiek
Subject Editor:
Further Information

Publication History

Publication Date:
05 July 2013 (online)

    Permissions and Reprints

Zusammenfassung

Johanniskraut ist eine der bekanntesten und am häufigsten eingesetzten Heilpflanzen mit breitem Indikationsspektrum. Die systemische und topische Anwendung dieses Phytopharmakons im onkologischen Kontext betrifft verschiedene Aspekte über die antidepressive Wirkung hinaus. Der folgende Beitrag gibt einen kurzen Überblick über den Einsatz in der supportiven Krebstherapie, der primär antitumorösen Therapie und potenzielle Nebenwirkungen durch Begleitphänomene wie die Phototoxizität und pharmakologische Interaktionen mit onkologischen Präparaten.

Summary

St. John’s wort in oncology: Perspectives on one of the best known phytotherapeutics
St. John’s wort is one of the best known and most widely used medicinal plants with a wide range of indications. The systemic and topical use of this phytopharmaceutical in oncology relates to various aspects that go beyond antidepressant effect. This article gives a brief overview of the use of supportive cancer therapy, the primary anticancer treatment and potential side effects through accompanying phenomena such as phototoxicity and pharmacological interactions with oncological drugs.

Schlüsselwörter

Johanniskraut - Hypericum perforatum L - Hypericin - Hyperforin - Photosensibilisierung - Wechselwirkungen - supportive Therapie

Key words

St. John’s wort - Hypericum perforatum L - hypericin - hyperforin - photosensibility - interactions - oncology - supportive therapy
 

  • Literatur

  • 1 Agostinis P, Vantieghem A, Merlevede W, de Witte PA. Hypericin in cancer treatment: more light on the way. Int J Biochem Cell Biol 2002; 34: 221-241
    CrossrefPubMedGoogle Scholar
  • 2 Augustin M. Phytotherapie bei Hauterkrankungen: Grundlagen – Praxis – Studien. München: Elsevier, Urban & Fischer; 2004
    Google Scholar
  • 3 Bernd A, Simon S, Bosca AR et al. Phototoxic effects of Hypericum extract in cultures of human keratinocytes compared with those of psoralen. Photochem Photobiol 1999; 69: 218-221
    CrossrefPubMedGoogle Scholar
  • 4 Boiy A, Roelandts R, van Den Oord J, de Witte PA. Photosensitizing activity of hypericin and hypericin acetate after topical application on normal mouse skin. Br J Dermatol 2008; 158: 360-369
    PubMedGoogle Scholar
  • 5 Boiy A, Roelandts R, de Witte PA. Photodynamic therapy using topically applied hypericin: Comparative effect with methylaminolevulinic acid on UV induced skin tumours. J Photochem Photobiol B 2011; 102: 123-131
    CrossrefPubMedGoogle Scholar
  • 6 Brockmoller J, Reum T, Bauer S et al. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997; 30 (Suppl. 2): 94-101
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Bublik M, Head C, Benharash P et al. Hypericin and pulsed laser therapy of squamous cell cancer in vitro. Photomed Laser Surg 2006; 24: 341-347
    CrossrefPubMedGoogle Scholar
  • 8 Buytaert E, Matroule JY, Durinck S et al. Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells. Oncogene 2007; 27: 1916-1929
    PubMedGoogle Scholar
  • 9 Chan PS, Koon HK, Wu ZG et al. Role of p38 MAPKs in hypericin photodynamic therapyinduced apoptosis of nasopharyngeal carcinoma cells. Photochem Photobiol 2009; 85: 1207-1217
    CrossrefPubMedGoogle Scholar
  • 10 Davids LM, Kleemann B, Kacerovská D et al. Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells. J Photochem Photobiol B 2008; 91: 67-76
    CrossrefPubMedGoogle Scholar
  • 11 Fiebich BL, Heinrich M, Langosch JM et al. Antibacterial activity of hyperforin from St John’s wort. Lancet 1999; 354: 777
    CrossrefPubMedGoogle Scholar
  • 12 Golsch S, Vocks E, Rakoski J et al. Reversible Erhöhung der Photosensitivität im UV-BBereich durch Johanniskrautextrakt-Präparate. Hautarzt 1997; 48: 249-252
    CrossrefPubMedGoogle Scholar
  • 13 Gulick RM, McAuliffe V, Holden-Wiltse J et al. Phase I studies of hypericin, the active compound in St. John’s Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258. Ann Intern Med 1999; 130: 510-514
    CrossrefPubMedGoogle Scholar
  • 14 Harris PE, Cooper KL, Relton C, Thomas KJ. Prevalence of complementary and alternative medicine (CAM) use by the general population: a systematic review and update. Int J Clin Pract 2012; 66: 924-939
    CrossrefPubMedGoogle Scholar
  • 15 Hübner J, Kleeberg U. Komplementäre Onkologie – ist ein evidenzbasierter Ansatz möglich und sinnvoll?. Onkologe 2009; 15: 173-176
    CrossrefPubMedGoogle Scholar
  • 16 Ippen H. Lichtschäden durch Arzneimittel. arznei-telegramm 1995; 10: 102
    PubMedGoogle Scholar
  • 17 Johne A, Mai I, Bauer S et al. Übersicht zu Interaktionsstudien mit Johanniskrautextrakten. In: Schulz V, Rietbrock N, Roots I, Loew D, Hrsg. Phytopharmaka VII. Darmstadt: Steinkopff; 2002: 149-161
    Google Scholar
  • 18 Johne A, Roots I. Woran sollte man denken bei der Gabe von Johanniskrautpräparaten?: Unerwünschte Arzneimittelwirkungen und -interaktionen. Pharmazie in unserer Zeit 2003; 32: 242-246
    CrossrefPubMedGoogle Scholar
  • 19 Kacerovská D, Pizinger K, Majer F, Šmíd F. Photodynamic therapy of nonmelanoma skin cancer with topical Hypericum perforatum extract – a pilot study. Photochem Photobiol 2008; 84: 779-785
    CrossrefPubMedGoogle Scholar
  • 20 Kamuhabwa AR, Agostinis PM, D’Hallewin MA et al. Cellular photodestruction induced by hypericin in AY-27 rat bladder carcinoma cells. Photochem Photobiol 2001; 74: 126-132
    CrossrefPubMedGoogle Scholar
  • 21 Kraft K. Aktuelle Entwicklungen bei Johanniskrautextrakten: Neue Daten zu Wirksamkeit und Interaktionen. Wien Med Wochenschr 2007; 157: 284-287
    CrossrefPubMedGoogle Scholar
  • 22 Linde K. St. John’s wort – an overview. Forsch Komplementmed 2009; 16: 146-155
    PubMedGoogle Scholar
  • 23 Lougheed C, Alaoui-Jamali M. Herbal product– drug interactions from a pharmacological perspective. In: Alaoui-Jamali M, ed. Alternative and Complementary Therapies for Cancer. Berlin: Springer US; 2010: 423-493
    Google Scholar
  • 24 Mai I, Bauer S, Perloff E et al. Hyperforin content determines the magnitude of the St John’s wort–cyclosporine drug interaction. Clin Pharmacol Ther 2004; 76: 330-340
    CrossrefPubMedGoogle Scholar
  • 25 Martirosyan AS, Vardapetyan HR, Tiratsuyan SG, Hovhannisyan AA. Biphasic dose-response of antioxidants in hypericin-induced photohemolysis. Photodiagnosis Photodyn Ther 2011; 8: 282-287
    PubMedGoogle Scholar
  • 26 Meinke MC, Schanzer S, Haag SF et al. In vivo photoprotective and anti-inflammatory effect of hyperforin is associated with high antioxidant activity in vitro and ex vivo. Eur J Pharm Biopharm 2012; 81: 346-350
    CrossrefPubMedGoogle Scholar
  • 27 Menichini G, Alfano C, Marrelli M et al. Hypericum perforatum L. subsp. perforatum induces inhibition of free radicals and enhanced phototoxicity in human melanoma cells under ultraviolet light. Cell Prolif 2013; 46: 193-202
    CrossrefPubMedGoogle Scholar
  • 28 Meyer S, Vogt T, Landthaler M, Karrer S. Einsatz von Phytopharmaka in der Dermatologie. Hautarzt 2005; 56: 483-502
    CrossrefPubMedGoogle Scholar
  • 29 Mueller SC, Majcher-Peszynska J, Mundkowski RG et al. No clinically relevant CYP3A induction after St. John’s wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol 2009; 65: 81-87
    CrossrefPubMedGoogle Scholar
  • 30 Münstedt K. Komplementäre und alternative Krebstherapien. 3. Aufl. Landsberg/Lech: Ecomed Medizin; 2012
    Google Scholar
  • 31 Nakajima N, Kawashima N. A basic study on Hypericin-PDT in vitro. Photodiagnosis Photodyn Ther 2012; 9: 196-203
    CrossrefPubMedGoogle Scholar
  • 32 Penjweini R, Loew HG, Eisenbauer M, Kratky KW. Modifying excitation light dose of novel photosensitizer PVP-Hypericin for photodynamic diagnosis and therapy. J Photochem Photobiol B 2013; 120: 120-129
    CrossrefPubMedGoogle Scholar
  • 33 Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med 2010; 40: 1797-1810
    CrossrefPubMedGoogle Scholar
  • 34 Putnik K, Stadler P, Schäfer C, Koelbl O. Enhanced radiation sensitivity and radiation recall dermatitis (RRD) after hypericin therapy – case report and review of literature. Radiat Oncol 2006; 1: 32
    CrossrefPubMedGoogle Scholar
  • 35 Rouis Z, Abid N, Koudja S et al. Evaluation of the cytotoxic effect and antibacterial, antifungal, and antiviral activities of Hypericum triquetrifolium Turra essential oils from Tunisia. BMC Complement Altern Med 2013; 13: 24
    CrossrefPubMedGoogle Scholar
  • 36 Schäfer M. Depressionen bei Patienten mit Tumorerkrankungen. Onkologe 2007; 13: 632-641
    CrossrefPubMedGoogle Scholar
  • 37 Schauder S. Phototoxische Reaktionen der Haut durch Medikamente. Dtsch Arztebl 2005; 102: A2314-2319
    PubMedGoogle Scholar
  • 38 Schempp C, Hezel S, Simon J. Behandlung der subakuten atopischen Dermatitis mit Johanniskraut-Creme. Der Hautarzt 2003; 54: 248-253
    PubMedGoogle Scholar